Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Oncol Rep ; 38(6): 3538-3544, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29039588

RESUMO

The aim of the present study was to identify cell types in primary culture from malignant and non-malignant effusions. Effusion samples were subjected to cytology and culture. Immunocytochemistry was performed in cytological slides to evaluate malignancy (positivity for malignancy markers) and in culture slides for identification of cell types in growth. A total of 143 effusion samples (pleural n=76; peritoneal n=37; pericardial n=4; and peritoneal lavage n=26) were analyzed. Cell growth was observed in 34.9% of all samples and immunocytochemistry for identification of cell types in culture slides was conclusive in 90% of them. In non-malignant samples (n=28), growth of mesothelial cells, macrophages and of both cell types was identified in 82.14, 10.71 and 7.14%, respectively. In malignant samples (n=17, all carcinomas), growth of malignant epithelial cells and of both malignant epithelial and mesothelial cells was identified in 41.17 and 23.52%, respectively. In the remaining 35.29% of malignant samples, the only cells in growth were mesothelial and/or macrophages instead of malignant epithelial cells. In conclusion, in culture of malignant effusions, mesothelial cells may be simultaneously identified with malignant epithelial cells. Besides, mesothelial cells and macrophages may be the only cells identified in malignant effusion culture. Therefore, a broad panel of cell markers should be used for unmistakable identification of cells in studies of effusion primary culture. The ideal malignant effusion sample to obtain culture of neoplastic cells should be that without the presence of mesothelial cells and macrophages.


Assuntos
Adenocarcinoma/genética , Citodiagnóstico , Mesotelioma/genética , Derrame Pleural Maligno/genética , Adenocarcinoma/patologia , Líquido Ascítico/metabolismo , Líquido Ascítico/patologia , Biomarcadores Tumorais/genética , Linhagem Celular Tumoral , Linhagem da Célula/genética , Proliferação de Células/genética , Feminino , Humanos , Masculino , Mesotelioma/patologia , Lavagem Peritoneal , Derrame Pleural Maligno/patologia
2.
J Cancer Res Clin Oncol ; 140(12): 2163-8, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25323937

RESUMO

BACKGROUND: The aim of this study was to evaluate the expression of IMP3, an independent poor prognostic factor for many cancers, and its association with clinicopathological features and HER2 status. METHODS: Gastrectomy specimens from 106 patients were evaluated by immunohistochemistry and fluorescence in situ hybridization. RESULTS: HER2 overexpression was found in 4.71 % of the samples. A negative association was observed between HER2 overexpression and grade of differentiation. No association was observed between HER2 overexpression and status of surgical margins, vascular invasion, perineural invasion, nodal metastasis and depth of invasion. Among all specimens of gastric cancer, 67.92 % were positive for IMP3. Expression of IMP3 was significantly higher in specimens with vascular invasion, perineural invasion, nodal metastasis and higher depth of invasion. HER2 overexpression was detected in only 5.55 % of IMP3 positive specimens. CONCLUSIONS: IMP3 expression was frequently observed in gastric cancer and was associated with poor prognostic clinicopathological features. A survival benefit with HER2 therapy should be expected for the minority of patients with IMP3 positive specimens. Studies should be conducted to evaluate the response to HER2 therapy of gastric cancer expressing IMP3.


Assuntos
Proteínas de Ligação a RNA/análise , Receptor ErbB-2/análise , Neoplasias Gástricas/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Prognóstico , Neoplasias Gástricas/química , Neoplasias Gástricas/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA